Technology Solutions Company Contact

Tod Woolf, Ph.D. President and Founder
Dr. Woolf founded IPIFINI in 2003 and also serves on the Scientific Advisory Board of Signet Laboratories. He founded and served as CEO of Sequitur, a biotechnology company acquired by Invitrogen (Nasdaq: IVGN) in 2003. Dr. Woolf holds a Masters and Doctorate in Biology from Harvard University. He has authored 40 patents and scientific publications and has given product development lectures throughout the world. Products co-developed by Dr. Woolf have been used in drug discovery efforts in most pharmaceutical companies and have generated over $100 million in revenues. Dr. Woolf at Cal Tech, invented the Beta-Safety Apron™ while at Harvard University, co-invented therapeutic RNA editing, Gene-blocks™ and lead therapeutic drugs at RPI (Nasdaq: RNAI). He co-invented Version D™ antisense compounds, Optimized Antisense™, Stealth RNAi™ and Ultramers™ at Sequitur.

Andrew Marks, Ph.D., J.D. VP of Technology Development
Dr. Marks has a B.S. from Cornell University, a Ph.D. in Cell and Molecular Biology from New York University School of Medicine and a J.D. from Fordham Law School. In 2003 Dr. Marks left the practice of law to pursue technology development full time. Dr. Marks spent ten years at the intellectual property firm Fish & Neave in New York as a patent agent and an associate. He also served as Chief Patent Counsel at Vertex Pharmaceuticals (Nasdaq: VRTX), a biopharmaceutical company in Cambridge, Massachusetts. Dr. Marks has extensive experience in licensing, corporate research & development partnerships and mergers and acquisitions.

Richard Gill, Ph.D. Licensing, Pharmaceuticals and Consumer Products
Dr. Gill has over 20 years of technology commercialization experience. He is currently CEO of Signet Laboratories. enterprise wide solution for pharmaceutical intellectual property licensing. He also served as President of the biotechnology company Genome Therapeutics Corp. (Nasdaq: GENE). Prior to this Dr. Gill served as Senior Vice President of BTG (LSE: BGC), a global leader in the patenting and commercialization of intellectual property rights. Earlier, he held research and management positions at Unilever. Dr. Gill holds a Ph.D. in Endocrinology and a BS in Physiology and Biochemistry.

Glenn Wachler Advisor
Mr. Wachler is the co-inventor of the Programmable Liquid Container for "Choice Enabling". He began his business career designing and selling custom jewelry. He then created a successful construction business in which he personally designs and builds unique waterfront homes. Mr. Wachler originated Ultimate Expression™ jeweled sculptures which meaningfully mark special occasions for "Modern Royalty". He writes essays and lectures on philosophy for which he is regularly featured on syndicated radio broadcasts.